E-Health & Innovation to Overcome Barriers in Neuromuscular Diseases. Report from the 1st eNMD Congress: Nice, France, March 22-23, 2019

Author:

Pini Jonathan1,Siciliano Gabriele2,Lahaut Pauline1,Braun Serge3,Segovia-Kueny Sandrine3,Kole Anna4,Hérnando Ines5,Selb Julij6,Schirinzi Erika2,Duong Tina7,Hogrel Jean-Yves8,Olmedo José Javier Serrano91011,Vissing John12,Servais Laurent1314,Vincent-Genod Dominique15,Vuillerot Carole16,Bannwarth Sylvie1718,Eggenspieler Damien19,Vicart Savine20,Diaz-Manera Jordi212223,Lochmüller Hanns242526,Sacconi Sabrina11827,

Affiliation:

1. Université Côte d’Azur (UCA), Centre Hospitalier Universitaire de Nice, Peripheral Nervous System and Muscle Department, Rare Neuromuscular Disease Reference Center, ERN-Euro-NMD, Nice, France

2. Neurological Clinic, Department of Clinical and Experimental Medicine, Ospedale Santa Chiara, University of Pisa, Pisa, Italy

3. AFM Telethon, Paris, France

4. Public Health Policy Director Rare 2030 Lead EURORDIS

5. Healthcare Director EURORDIS

6. University Clinic Golnik, Golnik, Slovenia –Medical consultant Parsek, Vienna, Austria

7. Department of Neurology Stanford University, Palo Alto, CA, USA

8. Neuromuscular Physiology and Evaluation Lab, Neuromuscular Investigation Centre, Institute of Myology, Paris, France

9. Laboratory of Bioinstrumentation and Nanomedicine, Center for Biomedical Technology, Universidad Politécnica de Madrid, Madrid, Spain

10. Networking Center for Biomedical Research on Bioengineering, Biomaterials and Nanomedicine, Madrid, Spain

11. Escuela Técnica Superior de Ingenieros de Telecomunicación, Madrid, Spain

12. Copenhagen Neuromuscular Center, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark

13. MDUK Oxford Neuromuscular Center Department of Pediatrics University of Oxford, Oxford, UK

14. Division of Child Neurology Reference Center for Neuromuscular Disease, Centre Hospitalier Régional de Références des Maladies Neuromusculaires, Department of Paediatrics, University, Oxford, UK

15. L’Escale, Pediatric Rehabilitation Department, Hospices Civils de Lyon, Lyon, France

16. Neuron Interaction Team, NeuroMyogène Institute, Lyon University, Lyon, France

17. Department of Medical Genetics, National Center for Mitochondrial Diseases, Nice University Hospital, Nice, France

18. Institute for Research on Cancer and Aging of Nice (IRCAN), Faculty of Medicine, Université Côte D’Azur (UCA), Nice, France

19. Healthcare Program Director, Sysnav, Paris, France

20. Channelopahies Reference Center, Service of Neuro-Myology, University Hospital Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Paris, France

21. John Walton Muscular Dystrophy Research Center, Newcastle University, Newcastle, UK

22. Neurology department. Hospital de la Santa Creu I Sant Pau, Barcelona, Spain

23. Centro de Investigación Biomédica en Red en Enfermedades Raras (CIBERER), Spain

24. Childrens Hospital of Eastern Ontario Research Institute; Division of Neurology, Department of Medicine, The Ottawa Hospital; and Brain and Mind Research Institute, University of Ottawa, Ottawa, Canada

25. Department of Neuropediatrics and Muscle Disorders, Medical Center –University of Freiburg, Faculty of Medicine, Freiburg, Germany

26. Centro Nacional de Análisis Genómico (CNAG-CRG), Center for Genomic Regulation, Barcelona Institute of Science and Technology (BIST), Barcelona, Catalonia, Spain

27. Fédération Hospitalo-Universitaire Oncoage, Centre Hospitalier Universitaire de Nice, Université Côte d’Azur (UCA), Nice, France

Abstract

By definition, neuromuscular diseases are rare and fluctuating in terms of symptoms; patients are often lately diagnosed, do not have enough information to understand their condition and be proactive in their management. Usually, insufficient resources or services are available, leading to patients’ social burden. From a medical perspective, the rarity of such diseases leads to the unfamiliarity of the medical staff and caregiver and an absence of consensus in disease assessment, treatment, and management. Innovations have to be developed in response to patients’ and physicians’ unmet needs. It is vital to improve several aspects of patients’ quality of life with a better comprehension of their disease, simplify their management and follow-up, help their caregiver, and reduce the social and economic burden for living with a rare debilitating disease. Database construction regrouping patients’ data and symptoms according to specific country registration on data privacy will be critical in establishing a clear consensus on neuromuscular disease treatment. Clinicians also need technological innovations to help them recognize neuromuscular diseases, find the best therapeutic approach based on medical consensus, and tools to follow patients’ states regularly. Diagnosis also has to be improved by implementing automated systems to analyze a considerable amount of data, representing a significant step forward to accelerate the diagnosis and the patients’ follow up. Further, the development of new tools able to precisely measure specific outcomes reliably is of the matter of importance in clinical trials to assess the efficacy of a newly developed compound. In this context, creation of an expert community is essential to communicate and share ideas. To this end, 97 clinicians, healthcare professionals, researchers, and representatives of private companies from 9 different countries met to discuss the new perspective and challenges to develop and implement innovative tools in the field of neuromuscular diseases.

Publisher

IOS Press

Subject

Neurology (clinical),Neurology

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. The challenges faced by patients with hereditary myopathy during the COVID-19 pandemic;International Journal of Palliative Nursing;2024-01-02

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3